Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
What is the purpose of this study?
FcRH5 is a new target in multiple myeloma, but it is almost universally expressed in myeloma patients making it an attractive target for new therapies.
In this video:
Dr. Adam Cohen talks about the initial clinical activity and safety of cevostamab, a FcRH5/CD3 T-Cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma.
The early findings show proof of principle although noting that it is too soon to say how it will fit into treatment options.
ASH 2020: Abstract 292
Adam Cohen, MD
Dr. Adam Cohen received his medical degree from the University of Pennsylvania, Philadelphia, where he also completed an internal medicine residency. He then completed a hematology/oncology fellowship, and was a research associate in the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center, New York. Dr. Cohen is currently an assistant professor, hematology/oncology division at Abramson Cancer Center of the University of Pennsylvania, Philadelphia.